SEC Form 4 · accession 0001171843-16-012249

IMMUNOMEDICS INC · IMMU

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President and CEO · Director

Period of report

Sep 21, 2016

Accepted (ET)

Sep 23, 2016 · 5:00 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000722830

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Sep 21, 2016	A	106,061	$0.00	A	794,320	D
Common Stock^F3	holding	—	—		—	5,254,286	I	See Footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F4	$3.30	Sep 21, 2016	A	199,532	D	—	Sep 21, 2023	Common Stock, par value $0.01 per share	199,532	199,532	D

F1Restricted stock units granted pursuant to the Immunomedics, Inc. 2014 Long-Term Incentive Plan, which vest as to 25% of the shares on the first anniversary of the date of grant and 6.25% of the shares on a quarterly basis thereafter.
F2Includes a total of 190,000 shares held as joint tenants by the reporting person and her spouse, David M. Goldenberg, the Issuer's Chief Scientific Officer, Chief Patent Officer, and Chairman of the Board of Directors.
F3Such shares are held by the reporting person's spouse, by various trusts established for the benefit of the reporting person and/or family members of the reporting person, or by a majority-owned subsidiary of the Issuer, of which the reporting person is an officer. The reporting person disclaims beneficial ownership of these shares except to the extent of her pecuniary interests therein.
F4Stock options granted pursuant to the Immunomedics, Inc. 2014 Long-Term Incentive Plan, which vest as to 25% of the shares underlying the options on the first anniversary of the date of grant and as to 6.25% of the shares underlying the options on a quarterly basis thereafter.